European Anticoagulants Market
European Anticoagulants Market Size, Share & Trends Analysis Report, By Type (Novel Oral Anticoagulants, Vitamin K Antagonist, and Heparin and Low Molecular Weight Heparin), By Application (Pulmonary Embolism, Atrial Fibrillation/Myocardial Infarction (Heart Attack), Deep Vein Thrombosis, and Others) and Forecast, 2020-2026 Update Available - Forecast 2024-2030
European anticoagulants market is estimated to grow at a CAGR of 6.6% during the forecast period. Rising prevalence of heart diseases is the major factor accelerating the market growth. As per the 2019 report from the European Society of Cardiology (ESC) Atlas, over 6 million new CVD cases reported in the EU. With nearly 49 million people suffering from CVD in the EU, it cost to the EU economies is high at nearly $255 billion annually. This, in turn, is resulting in an increasing demand for anticoagulants medicines used to prevent the blood from clotting as rapidly or as potentially as normal. Anticoagulants are also known as blood thinners. These medications are used for the treatment and prevention of blood clots that may occur in the blood vessels. Therefore, anticoagulants are utilized for the prevention of blood clots and atrial fibrillation (AF) is the most common condition in which blood clots are formed.
Visit for Global Anticoagulants Market Report at: https://www.omrglobal.com/industry-reports/anticoagulants-market
The market is segmented based on type and application. Based on type, the market is classified into novel oral anticoagulants (NOACs), vitamin k antagonist, and heparin, and low molecular weight heparin (LMWH). The use of novel oral anticoagulants (NOACs) is growing significantly in Europe owing to their advantages over older drugs including warfarin. NOACs has demonstrated tremendous safety and efficacy without the requirement of subsequent dose adjustment and frequent monitoring. Based on application, the market is classified into pulmonary embolism, atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis, and others.
Some key players in the market include Johnson & Johnson Services, Inc., Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH. In November 2020, Boehringer Ingelheim declared the European Medicines Agency’s (EMA) Committee has adopted a positive opinion for Pradaxa (dabigatran etexilate) to treat venous thromboembolic events (VTE) and prevention of recurrent VTE in pediatric patients from birth to less than 18 years of age.
Research Methodology
The market study of the European anticoagulants market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
- European Anticoagulants Market Research and Analysis by Type
- European Anticoagulants Market Research and Analysis by Application
The Report Covers
- Comprehensive research methodology of the European anticoagulants market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the European anticoagulants market.
- Insights about market determinants that are stimulating the European anticoagulants market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Country
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. European Anticoagulants Market by Type
5.1.1. Novel Oral Anticoagulants (NOACs)
5.1.2. Vitamin K Antagonist
5.1.3. Heparin and Low Molecular Weight Heparin (LMWH)
5.2. European Anticoagulants Market by Application
5.2.1. Pulmonary Embolism
5.2.2. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
5.2.3. Deep Vein Thrombosis (DVT)
5.2.4. Others
6. Regional Analysis
6.1. UK
6.2. Germany
6.3. France
6.4. Spain
6.5. Italy
6.6. Rest of European
7. Company Profiles
7.1. AstraZeneca plc
7.2. Bayer AG
7.3. Boehringer Ingelheim GmbH
7.4. Bristol Myers Squibb Co.
7.5. Daiichi Sankyo Company, Ltd.
7.6. GlaxoSmithKline plc
7.7. Mylan N.V.
7.8. Novartis International AG
7.9. Pfizer Inc.
7.10. Sanofi S.A.
1. EUROPEAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
2. EUROPEAN NOVEL ORAL ANTICOAGULANTS(NOACs) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
3. EUROPEAN VITAMIN K ANTAGONIST ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
4. EUROPEAN HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN (LMWH) ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
5. EUROPEAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
6. EUROPEAN ANTICOAGULANTS IN PULMONARY EMBOLISM MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
7. EUROPEAN ANTICOAGULANTS IN ATRIAL FIBRILLATION/MYOCARDIAL INFARCTION (HEART ATTACK) MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
8. EUROPEAN ANTICOAGULANTS IN DEEP VEIN THROMBOSIS (DVT) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
9. EUROPEAN ANTICOAGULANTS IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
10. EUROPEAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
11. UK ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
12. UK ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
13. GERMANY ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
14. GERMANY ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
15. FRANCE ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
16. FRANCE ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
17. SPAIN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
18. SPAIN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
19. ITALY ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
20. ITALY ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
21. REST OF EUROPEAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
22. REST OF EUROPEAN ANTICOAGULANTS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
1. EUROPEAN ANTICOAGULANTS MARKET SHARE BY TYPE, 2019 VS 2026 (%)
2. EUROPEAN NOACs MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
3. EUROPEAN VITAMIN K ANTAGONIST ANTICOAGULANTS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
4. EUROPEAN HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN (LMWH) ANTICOAGULANTS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
5. EUROPEAN ANTICOAGULANTS MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)
6. EUROPEAN ANTICOAGULANTS IN PULMONARY EMBOLISM MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
7. EUROPEAN ANTICOAGULANTS IN ATRIAL FIBRILLATION/MYOCARDIAL INFARCTION (HEART ATTACK) MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)
8. EUROPEAN ANTICOAGULANTS IN DEEP VEIN THROMBOSIS (DVT)MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
9. EUROPEAN ANTICOAGULANTS IN OTHER APPLICATIONS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
10. EUROPEAN ANTICOAGULANTS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
11. UK ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
12. GERMANY ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
13. FRANCE ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
14. SPAIN ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
15. ITALY ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF EUROPEAN ANTICOAGULANTS MARKET SIZE, 2019-2026 ($ MILLION)
